Selective factor Xa inhibition for thromboprophylaxis

被引：15

作者：

Eikelboom, John W. ^{[1
]}

Weitz, Jeffrey I. ^{[1
]}

机构：

[1] McMaster Univ, Hamilton, ON L9K 1H8, Canada

来源：

LANCET | 2008年 / 372卷 / 9632期

关键词：

D O I：

10.1016/S0140-6736(08)60879-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6 / 8

页数：3

共 11 条

[1]

*BAYER HEALTHC, 2008, PREV THROMB KNEE REP

[2] A replacement for warfarin - The search continues [J].

Eikelboom, John W. ;

Weitz, Jeffrey I. .

CIRCULATION, 2007, 116 (02) :131-133

[3] Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a metaanalysis of the randomised trials [J].

Eikelboom, JW ;

Quinlan, DJ ;

Douketis, JD .

LANCET, 2001, 358 (9275) :9-15

[4] Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement:: a randomised, double-blind, non-inferiority trial [J].

Eriksson, Bengt I. ;

Dahl, Ola E. ;

Rosencher, Nadia ;

Kurth, Andreas A. ;

van Dijk, C. Niek ;

Frostick, Simon P. ;

Prins, Martin H. ;

Hettiarachchi, Rohan ;

Hantel, Stefan ;

Schnee, Janet ;

Bueller, Harry R. .

LANCET, 2007, 370 (9591) :949-956

[5]

ERIKSSON BI, 2007, ORAL RIVAROXABAN COM

[6] Prevention of venous thromboembolism [J].

Geerts, WH ;

Pineo, GF ;

Heit, JA ;

Bergqvist, D ;

Lassen, MR ;

Colwell, CW ;

Ray, JG .

CHEST, 2004, 126 (03) :338S-400S

[7] New anticoagulants for treatment of venous thromboembolism [J].

Gross, Peter L. ;

Weitz, Jeffrey I. .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (03) :380-386

[8]

KAKKAR AK, 2008, LANCET 0625, DOI DOI 10.1016/S0140-6736(08)60880-6

[9]

LASSEN MR, 2007, RIVAROXABAN ORAL DIR

[10] Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases [J].

Turpie, Alexander G. G. .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (06) :1238-1247

← 1 2 →